Open AccessLocal consolidative therapy may be beneficial in patients with oligometastatic non‐small cell lung cancer
Author(s) -
Barton Mary Kay
Publication year - 2017
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21363
Subject(s) - lung cancer , medicine , systemic therapy , oncology , selection (genetic algorithm) , disease , cancer , intensive care medicine , medical physics , computer science , artificial intelligence , breast cancer
Key Points PFS was found to be significantly increased with the use of local consolidative therapy in patients with oligometastatic NSCLC with stable or responding disease after standard frontline systemic therapy. This study provides evidence that is in keeping with an increasingly common approach in patients with advanced NSCLC. Larger studies and longer follow‐up are needed to confirm an overall survival advantage and improve patient selection.